Todd Asset Management LLC grew its stake in shares of Celgene Co. (NASDAQ:CELG) by 36.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 299,134 shares of the biopharmaceutical company’s stock after purchasing an additional 79,321 shares during the period. Todd Asset Management LLC’s holdings in Celgene were worth $26,770,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Ayalon Holdings Ltd. purchased a new stake in shares of Celgene during the second quarter valued at $100,000. Atlantic Trust LLC purchased a new stake in shares of Celgene during the second quarter valued at $101,000. Moneta Group Investment Advisors LLC lifted its holdings in shares of Celgene by 2,688.6% during the second quarter. Moneta Group Investment Advisors LLC now owns 10,290 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 9,921 shares during the last quarter. Harvest Fund Management Co. Ltd purchased a new stake in shares of Celgene during the third quarter valued at $132,000. Finally, City Holding Co. purchased a new stake in shares of Celgene during the second quarter valued at $143,000. 73.87% of the stock is owned by institutional investors and hedge funds.
CELG stock traded up $0.02 during mid-day trading on Monday, hitting $69.67. The stock had a trading volume of 36,750 shares, compared to its average volume of 7,321,889. The company has a debt-to-equity ratio of 4.06, a current ratio of 2.13 and a quick ratio of 1.99. Celgene Co. has a 1-year low of $68.91 and a 1-year high of $110.81. The firm has a market cap of $48.70 billion, a P/E ratio of 10.17, a PEG ratio of 0.43 and a beta of 1.53.
Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.02 by $0.27. Celgene had a return on equity of 108.76% and a net margin of 19.64%. The company had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.83 billion. As a group, research analysts expect that Celgene Co. will post 7.45 EPS for the current year.
Several equities research analysts have recently commented on CELG shares. Morgan Stanley upped their target price on Celgene from $91.00 to $93.00 and gave the company an “equal weight” rating in a report on Friday, July 27th. SunTrust Banks reissued a “hold” rating and issued a $101.00 price objective on shares of Celgene in a research note on Friday, July 27th. Mizuho reissued a “buy” rating and issued a $129.00 price objective on shares of Celgene in a research note on Tuesday, July 31st. Zacks Investment Research raised Celgene from a “sell” rating to a “strong-buy” rating and set a $102.00 price objective for the company in a research note on Wednesday, August 1st. Finally, BidaskClub raised Celgene from a “hold” rating to a “buy” rating in a research note on Thursday, August 16th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. Celgene presently has a consensus rating of “Buy” and an average target price of $116.99.
ILLEGAL ACTIVITY NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/11/19/todd-asset-management-llc-has-26-77-million-stake-in-celgene-co-celg.html.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Recommended Story: Earnings Per Share
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.